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Community-acquired pneumonia (CAP) remains a common and serious illness with approximately 2–4 million
cases reported annually. Management of CAP is therapeutically challenging due to the increasing prevalence of
penicillin- and macrolide-resistant pneumococci and b-lactamase producing Haemophilus influenzae, as well as the
increased recognition of ‘atypical’ pathogens, such as Chlamydia pneumoniae andMycoplasma pneumoniae, and the
frequent need for empiric therapy.
We aimed to evaluate the safety and ecacy of moxifloxacin in the treatment of patients with CAP. To do this we
carried out a prospective, uncontrolled, non-blind, Phase III clinical trial, in 27 U.S. centers. Patients included in
the study were over 18 years of age with signs and symptoms of CAP confirmed by evidence of a new or progressive
infiltrate on chest radiograph. The intervention used was moxifloxacin 400 mg PO once daily for 10 days.
Sputum samples were collected pretherapy for Gram stain and culture for typical organisms. Culture and
serological testing for Chlamydia pneumoniae and Mycoplasma pneumoniae was also performed. Susceptibility to
moxifloxacin was determined by disk diusion and MIC. Clinical and bacteriological responses were determined at
the end of therapy (0–6 days post-therapy), follow-up (14–35 days post-therapy) and overall (end of therapy plus
follow-up). Analyses were performed on both valid for ecacy and intent-to-treat populations. The primary
ecacy variable was overall clinical resolution.
Of 254 patients enrolled in the Study, 196 patients were included in the ecacy analyses. The majority of patients
were male (58%) and Caucasian (85%) with a mean age of 49 years (range: 18 to 85 years). Only 3% of patients
were hospitalized pretherapy. The most common pretherapy organisms identified, by culture or serology, in the
valid for ecacy population (i.e. 147 organisms among 116 patients), were: Chlamydia pneumoniae (n63; 54%),
Mycoplasma pneumoniae (n29; 25%), Streptococcus pneumoniae (n14; 12%) and Haemophilus influenzae (n13;
10%). End of therapy, follow-up and overall clinical resolution rates for the valid for ecacy population were 94%,
93% and 93%, respectively. The 95% CI for the overall clinical resolution rate was 881%, 959%. The overall
bacteriological response for patients diagnosed by culture or serological criteria, was 91% (95% CI84%, 96%).
For patients who only met serological criteria for infection, the overall bacteriological response was 94% (60/64).
Bacterial response rates for the four most commonly isolated pathogens were: 89% (56/63) for C. pneumoniae, 93%
(27/29) forM. pneumoniae, 93% (13/14) for S. pneumoniae and 85% (11/13) for H. influenzae. Drug-related adverse
events were reported in 33% (85/254) of moxifloxacin-treated patients. Nausea (9%), diarrhea (6%) and dizziness
(4%) were the most commonly reported adverse events.
Atypical organisms were isolated in high frequency among patients with CAP. Moxifloxacin 400 mg once daily
for 10 days was eective and well-tolerated in the treatment of these adult patients with CAP. Moxifloxacin oers
an eective treatment alternative for CAP due to both typical and atypical bacterial pathogens.
Key words: Chlamydia pneumoniae; community-acquired pneumonia; clinical trial; atypical organisms; moxiflox-
acin; Mycoplasma pneumoniae.
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Community-acquired pneumonia (CAP) is a common and
serious illness in the U.S.A. with approximately 2–4 million
cases of CAP occurring annually, with the majority of
patients treated in the outpatient setting (1). At least 10
million physician visits per year are the result of CAP (1).# 2000 HARCOURT PUBLISHERS LTD
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the U.S.A. (2) the mortality rate of pneumonia treated in
the outpatient setting remains low (1–5%) compared to a
rate as high as 25% for patients who require hospitalization
(3,4). Of additional significance is a recent retrospective
analysis which revealed that $48 billion is spent annually
treating CAP patients465 years of age and $3.6 billion for
those less than 65 years of age (5). In Niederman’s survey,
annual outpatient costs were $119 million and $266 million,
respectively. Consequently, use of eective therapy in the
outpatient setting can reduce the overall cost burden for
CAP.
A rapid etiological diagnosis is optimal in the manage-
ment of CAP. However, the pathogen responsible for CAP
is not identified in as many as 50% of patients even when
extensive diagnostic testing is performed (6,7). In many
earlier studies involving adults, Streptococcus pneumoniae
was the most commonly isolated pathogen, accounting for
up to two-thirds of CAP cases, followed by non-type b
Haemophilus influenzae (8). Other less commonly isolated
organisms included Staphylococcus aureus, Streptococcus
pyogenes, Neisseria meningitidis, Moraxella catarrhalis and
Klebsiella pneumoniae (7). In some recent studies, pneumo-
coccus has been recovered less frequently with a concomi-
tant rise in recognition of ‘atypical’ agents such as
Chlamydia pneumoniae, Mycoplasma pneumoniae and Le-
gionella pneumophila (8). The infection rate for these
atypical pathogens tends to vary greatly depending upon
the patient’s age as well as temporal and geographical
patterns (9).
Despite advances in diagnosis and therapy, the manage-
ment of pneumonia still represents a challenge to the
physician. Parallel to the availability of numerous new
antimicrobials, bacterial resistance mechanisms have
evolved. In the 1990s, pneumococcal resistance to penicillin
G and other antimicrobials has increased dramatically, as
well as ampicillin resistance due to the increasing pre-
valence of b-lactamase-producing H. influenzae and M.
catarrhalis. Specifically, several studies in the U.S.A. have
documented that approximately 40% of H. influenzae and
495% of M. catarrhalis produce b-lactamase enzymes and
420% of S. pneumoniae are highly resistant to penicillin
(10–14).
A 1994–1995 survey of 30 U.S. centers reported a
penicillin-resistant S. pneumoniae rate of approximately
23% (10). This survey also found 34% of pneumococcal
isolates to be resistant to cefotaxime and approximately 4–
8% of isolates to be resistant to tetracycline and macrolide
antimicrobials. In a second survey of penicillin-resistant
pneumococcal isolates from the 1995–96 ‘respiratory
season’, fluoroquinolones were found to be very active
against all isolates of S. pneumoniae (sensitive, intermediate
and resistant) (15). In the same study, with the exception of
vancomycin and fluoroquinolones, all b-lactams and
macrolides tested demonstrated decreased susceptibility
with increasing penicillin resistance (16). Another survey
conducted by Thornsberry et al. 1996–97 reported a further
rise in resistance levels with approximately 34% of 9190
pneumococcal isolates penicillin-resistant (17). Importantly,
these isolates were collected from adults during the‘respiratory season’. In the same study, many penicillin-
resistant pneumococcal strains showed intermediate or
high-level resistance to relatively newer b-lactams and
macrolides including amoxicillin-clavulanate, cefuroxime,
ceftriaxone and clarithromycin (16). These findings all
suggest the need for antimicrobial alternatives for the
treatment of respiratory tract pathogens.
The objective of this study was to evaluate the safety and
ecacy of moxifloxacin, a new 8-methoxyfluoroquinolone,
administered at 400 mg PO once daily for 10 days in the
treatment of patients with CAP. Moxifloxacin has excellent
in vitro and in vivo animal model activity against the
organisms commonly implicated in CAP. For S. pneumo-
niae, the reported MIC90 for moxifloxacin ranges from
012–025 g ml71, including penicillin-resistant isolates,
which is at least four-fold more active than ciprofloxacin
(17). The MIC90 values for H. influenzae andM. catarrhalis
are each 006 g ml71 and are not influenced by b-
lactamase production (17). Preliminary moxifloxacin data
indicate that both Chlamydia and Mycoplasma species
are inhibited with an MIC510 g ml71 (range of 006 to
10 g ml71) (18). Importantly, single oral moxifloxacin
doses have been reported to be safe and well tolerated in
Phase I pharmacokinetic studies (19–21).
Methods
STUDY DESIGN AND PATIENTS
We conducted a prospective, open-label, multi-center,
Phase III clinical trial of the ecacy and safety of
moxifloxacin in the treatment of adult patients with CAP.
Patients were given oral moxifloxacin 400 mg daily for 10
days as supplied by Bayer Corporation Pharmaceutical
Division, West Haven, CT, U.S.A.
Patients (18 years or older) with CAP documented by the
presence of fever and/or elevated white blood cell count
(410 000 mm73) and/or leukocytosis, signs or symptoms
of pneumonia [productive cough, purulent sputum, dys-
pnea or tachypnea (420 breaths min71), rigors/chills,
pleuritic chest pain, or signs of pulmonary consolidation]
and a new or progressive infiltrate on chest radiograph were
enrolled. Patients with any of the following characteristics
were excluded: allergy to fluoroquinolones; pregnancy or
lactation; presence of severe pneumonia requiring parent-
eral antimicrobials or mechanical ventilatory support;
suspected aspiration pneumonia due to vomiting; hospita-
lization; significant liver or renal impairment or severe heart
failure; impaired host defenses (e.g. neutropenia or low
CD4 count); history of fluoroquinolone tendinopathy;
more than 24 h of systemic antibiotic therapy for the
current episode of CAP during study screening or require-
ment for concomitant antibacterial therapy; rapidly fatal
underlying disease; other confounding respiratory disease
(e.g. lung cancer); history of prolonged QTc interval or
requiring concomitant medication associated with increased
QTc interval; administration of another investigational
drug within 30 days of study enrollment; or previous
enrollment in this study.
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review board, and written informed consent was obtained
from each patient prior to enrollment.
CLINICAL AND LABORATORY
EVALUATIONS
Eligible patients were to be evaluated at four visits:
pretherapy (within 48 h of first study drug dose), during
treatment (days 3–5), at the end of therapy (0–6 days post-
therapy) and at follow-up (14–35 days post-therapy) with
clinical signs and symptoms noted at each visit. Chest
radiographs were obtained at baseline and were repeated at
each visit until there was evidence of infiltrate resolution.
Blood and urine samples were collected for routine
hematological, chemistry coagulation and urinalysis eva-
luations. In addition, ECGs were performed at the
pretherapy and during therapy visits.
Sputum samples were collected at each visit by deep
expectoration, as available, and submitted to a local
laboratory for Gram stain and culture. Cultures were to
be performed on appropriate specimens if the Gram stain
revealed 10 squamous epithelial cells and 25 leukocytes
per low power field. Patients were treated empirically, prior
to receipt of culture and susceptibility testing results. If,
after treatment had begun, susceptibility test results did not
demonstrate the organism to be susceptibile to moxiflox-
acin and the patient was not responding clinically, the
investigator had the option of withdrawing the patient from
the study. Tentatively, for M. catarrhalis, Haemophilus spp
and S. pneumoniae, an MIC of 2 g ml71 and a zone
diameter of 12 mm were considered borderline results for
moxifloxacin. Susceptibility testing for moxifloxacin in-
cluded MIC determinations by standardized Etest and
Kirby Bauer disk diusion methods (22). Isolates of M.
catarrhalis and Haemophilus spp. were tested for produc-
tion of b-lactamase and penicillin susceptibility was
determined for S. pneumoniae isolates.
The following diagnostic tests were performed at the
pretherapy visit to identify atypical pathogens. Serum
samples were collected for serology (C. pneumoniae and
M. pneumoniae) at pretherapy, end of therapy and follow-
up visits. Serodiagnosis of acute C. pneumoniae infection
was based on an established algorithm that required any
one of the following three criteria be satisfied: 1. Four-fold
increases in IgG between any two visits, 2. IgM1:32 at any
visit and 3. IgG1:512 at any visit. Serodiagnosis of acute
M. pneumoniae infection was based on an established
algorithm that required that any one of the following three
criteria: 1. IgM1:10 at any visit, 2. four-fold increase in
IgG between any two visits and 3. IgG51:10 at pretherapy
and 1:10 at any follow-up visit (27). Serological detection
of IgM and IgG antibodies for C. pneumoniae was by
micro-immunofluorescence assay (Chlamydia Research
Laboratory, San Francisco, CA, U.S.A.) (27). Serological
detection ofM. pneumoniae IgM and IgG antibodies was by
enzyme immunoassay (EIA) (Diagnostic Mycoplasma
Laboratory, Birmingham, AL, U.S.A.). In addition, one
nasopharyngeal specimen was obtained for the isolation ofC. pneumoniae (State U. of New York Health Center,
Brooklyn, NY, U.S.A.). Two throat swabs were obtained
for the isolation of M. pneumoniae and if sucient sputum
was available, culture and identification of polymerase
chain reaction (PCR) was also performed (Diagnostic
Mycoplasma Laboratory). L. pneumophila was to be
identified using a urinary antigen EIA and a sputum
culture.
EFFICACY ENDPOINTS
The eectiveness of the study drug was determined by
assessing the patients’ clinical response and the presumed or
documented bacteriological response of the infecting
organism. Clinical response was determined by the inves-
tigator based on assessment of signs and symptoms of
pneumonia at the end of therapy (0–6 days after last dose of
study drug) and follow-up (14–35 days after last dose
of study drug) visits.
The bacteriological response was defined as eradication
when the initial pathogen was absent after treatment or at
follow-up, and was defined as persistence when the initial
pathogen remained after treatment regardless of clinical
response. In many cases, a post-treatment sputum specimen
was not available because of resolution of productive cough
and the bacteriological response was considered to be
presumed eradication or presumed persistence as deter-
mined by clinical response.
All patients receiving the study drug for any length of
time were evaluated for drug safety (intent-to-treat
population). Safety of study drug therapy was monitored
by clinical observations and by conventional laboratory
tests as described above. Adverse events were rated by the
investigator as to their severity (mild, moderate, severe),
and by the relationship to the study drug (probable,
possible, remote, or none).
In addition to the primary analysis of the valid for
ecacy population (i.e. patients with or without a
pretherapy pathogen), additional analyses were performed
for the population considered to be clinically and bacter-
iologically valid (i.e. all patients with a pretherapy
pathogen) and for the intent-to-treat population (i.e. all
patients who received at least one dose of study drug).
STATISTICAL ANALYSIS
To be considered valid for ecacy, the patients must have
met protocol criteria for CAP, not have protocol violations
influencing ecacy have been compliant with study
medication for at least 5 consecutive days (unless a
treatment failure) and have a follow-up clinical assessment
at least 14 days after completing therapy (unless a failure).
Statstical analyses were performed to determine the
clinical response in the valid for ecacy population and
the intent-to-treat population. The intent-to-treat popula-
tion was defined as all patients who received at least one
dose of study drug. The primary ecacy variable in this
study was the overall clinical response (Table 1).
TABLE 1. Overall clinical response
End of therapy evaluation Follow-up evaluation Overall clinical response
Resolution Continued Resolution Resolution
Failure — Failure
Resolution or indeterminate Relapse Failure
TABLE 2. Demographic and baseline medical characteristics
Moxifloxacin
400 mg (n196)
Sex, no. (%) male 113 (58%)
Race no. (%) Caucasian 167 (85%)
General health status
Fair 83 (42%)
Poor 40 (20%)
% not hospitalized pretherapy 190 (97%)
Mean age (years) at enrollment (range) 49 (18–85)
History of smoking, Yes 108 (55%)
Cigarette smoker, Yes 104 (53%)
Average number cigarettes smoked/day 21
Mean years of cigarette smoking 26
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considered a failure and at least 5 days of therapy to be
considered a success. All failure assessments were carried
forward. A more detailed definition of clinical response
categories is provided in Table 4.
Secondary ecacy parameters included overall bacter-
iological response, as well as bacteriological and clinical
responses at end of therapy. A two-sided 95% confidence
interval (CI) was constructed around the mean clinical
success rate using a normal approximation with continuity
correction as described in Fleiss (23).
Stastistical summaries were provided for demographic
and baseline characteristics, including means, standard
deviations, medians and quartiles for quantitative data, or
frequency counts for categorical data.
Safety analyses included tabulations of type, frequency,
duration and drug relatedness of treatment-emergent
events. In addition, laboratory data were analyzed using
descriptive statistics and values occurring outside of normal
ranges were identified.
Results
Two hundred and fifty-four patients were enrolled from 27
medical centers between December 1996 and May 1998
from multiple geographical areas of the U.S.A. All patients
received at least one dose of the study drug and were
thereby included in the intent-to-treat population. The
primary valid for ecacy population for overall clinical
response consisted of 196 (77%) patients. One hundred and
sixteen (46%) patients were valid for ecacy and were
considered microbiologically-valid because of identification
of causative pathogens by culture or serology.
Fifty-eight patients (23%) were excluded from the
ecacy analysis. The primary reasons for exclusion were
insucient duration of therapy (n14), violation of
inclusion/exclusion criteria (n12) and missing or invalid
ecacy data for the primary time point (n11). The
inclusion/exclusion violations were lack of an abnormal
chest radiograph at pretherapy consistent with pneumonia
(n6), insucient pneumonia symptoms at entry (n3) and
presence of lung cancer or neutropenia (n3). Twenty-six
patients were discontinued from the study prematurely. The
most frequent reasons for early discontinuation included
adverse events [n18 (see safety below)] and protocol
violations (n7). Ten patients were hospitalized after the
start of therapy, only five of which were valid for ecacy.The baseline demographic and medical characteristics for
the overall clinical valid for ecacy population are
summarized in Table 2. Among 196 patients, the majority
were male (58%) and Caucasian (85%) with a mean age of
49 years. Less than 3% of patients were hospitalized prior
to receiving study drug therapy. Smoking history (current
or past) was reported by more than half of valid for ecacy
patients. Pretherapy antibacterials were taken by 19 of 196
(10%) patients. The pretherapy symptoms reported in-
cluded 80% of patients with rigors/chills, 99% with cough
and 61% with pleuritic chest pain. The prevalence of the
following signs at presentation was reported for the valid
for ecacy population: rales (72%) ronchi (72%) and
dullness to percussion (39%).
PRETHERAPY CAUSATIVE ORGANISMS
A total of 147 of 254 (58%) enrolled patients had 190
organisms identified by either serological or culture
methods. One hundred and forty-seven pathogens were
identified from 59% (116 of 196) of patients who were valid
for ecacy.
Pretherapy causative organisms, by culture or serological
criteria, for the valid for ecacy group are outlined in
Table 3. Among the 116 patients with pretherapy organ-
isms, 61 were identified by serology only, 74 by culture,
with or without serology, and 19 by both methods. C.
pneumoniae was the most frequently identified organism
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patients; 25%). The most frequently isolated typical
respiratory tract pathogens were S. pneumoniae (14/116
patients; 12%) and H. influenzae (13/116 patients; 11%).
Of the 63 patients considered to have causative C.
pneumoniae by either method, three had both positive
serology and a causative pretherapy C. pneumoniae culture
isolate, 57 had only positive serology and three had only
positive pretherapy culture. Of the 29 patients considered to
have causative M. pneumoniae, 14 had both positive
serology and a causative pretherapy M. pneumoniae culture
isolate, seven had only positive serology and eight had only
positive pretherapy culture.TABLE 3. Causative organisms at pretherapy as determined by s
Organism
Serolo
n
Chlamydia pneumoniae{
Mycoplasma pneumoniae{
Streptococcus pneumoniae N
Haemophilus influenzae N
Staphylococcus aureus N
*More than one organism was considered causative for several
{Three patients met serological criteris for both C. pneumoniae a
1:128 (IgM) and 1:256 (IgG) post-therapy vs. not detectable at ba
end of therapy and 1:160 (IgM) and 1:10 (IgG) post therapy vs
1:512 (IgG) post therapy vs. 1:256 (IgG) baseline; Mycoplasma
therapy. In patient B, IgM titers were not detectable for both p
1:16 (IgM) and 1:512 (IgG) post therapy vs. 1:64 (IgM) and 1:51
and IgM each51:10) at all time points except for an IgM titer o
NA: not applicable.
TABLE 4. Clinical responses at end of therapy, follow-up and ov
End of Therapy (0–6 days post-therapy) Re
Fa
Follow-up (14–35 days post-therapy) Co
Fa
Re
Overall{ Re
Fa
*Indeterminate responses were excluded. Clinical Response Defi
sucient improvement in pneumonia signs/symptoms such th
required); failure (insucient lessening of signs/symptoms r
continued resolution (continued clinical cure as defined above)
visit). Indeterminate clinical responses {95% CI88.1%, 959%Clinical response
Among 196 patients who made up the primary ecacy
population, the overall clinical resolution rate was approxi-
mately 93% (95% CI88%, 96%). Similar rates were
found at the end of therapy and follow-up visits (Table 4).
Among the 212 patients who were valid at the end of
therapy time point, clinical resolution was 97% (95%
CI94%, 99%). For the microbiologically valid popula-
tion, a clinical resolution rate was observed in 110 of 116
patients (95%), including the one patient with a penicillin-
resistant pathogen at study entry. For patients with CAP
due to atypical organisms, the clinical resolution rate waserological criteria for acute infection or culture*
Culture-positive
gy only
61
(+positive serology)
n74
57 6
7 22
A 14
A 13
A 9
patients.
ndM. pneumoniae infection. Patient A: Chlamydia titers were
seline;Mycoplasma titers were 1:640 (IgM) and 1:80 (IgG) at
. not detectable at baseline. Patient B: Chlamydia titers were
titers were 1:40 (IgG) at end of therapy and 1:20 (IgG) post
athogens at all time points. Patient C: Chlamydia titers were
2 (IgG) baseline;Mycoplasma titers were not detectable (IgG
f 1:20 at baseline and an IgG titer of 1:10 at end of therapy.
erall
Moxifloxacin 400 mg
(n196)
n (%)*
solution 184 (96.8)
ilure 6 (3.2)
ntinued resolution 182 (95.8)
ilure 2 (1.0)
lapse 6 (3.2)
solution 182 (92.9)
ilure 14 (7.1)
nitions: resolution (clinical cure defined as disappearance or
at additional or alternative antimicrobial therapy was not
equiring additional or alternative antimicrobial therapy);
; relapse (reappearance of signs and symptoms at follow-up
.
TABLE 5. Overall bacterial eradication* by organism
(including patients who only met serological criteria)
Moxifloxacin 400 mg
(n116)
No. organisms eradicated
/total no, organisms (%)
Chlamydia pneumoniae 56/63 (89%)
Mycoplasma pneumoniae 27/29 (93%)
Streptococcus pneumoniae 13/14 (93%)
Haemophilus influenzae 11/13 (85%)
Staphylococcus aureus 8/9 (89%)
Moraxella catarrhalis 4/4 (100%)
Klebsiella pneumoniae 4/4 (100%)
*Bacteriological response was defined as eradicated if the
pathogen was absent from a culture of sputum and
presumed eradicated if obtainable sputum was inadequate
because of clinical cure or improvement. Rates shown are
the combined eradicated and presumed eradicated re-
sponses.
TABLE 6. Incidence rates of drug-related adverse events
occurring in  2% of patients
Adverse event Moxifloxacin 400 mg
(n254)
Headache 8 (3%)
Abdominal pain 4 (2%)
Nausea 22 (9%)
Diarrhea 16 (6%)
Vomiting 6 (2%)
Rash 4 (2%)
Dizziness 10 (4%)
Insomnia 5 (2%)
102 T. PATEL ET AL.93% (76/82). Patients infected only with typical organisms
had a 100% clinical resolution rate. Clinical resolution
was490% for all demographic and medical characteristics
subgroups, except for those of Hispanic origin (82%) and
patients445 years of age (89%). For the intent-to-treat
population, the overall clinical resolution rate was identical
to that of the ecacy valid group (93%; 95% CI89%,
96%).
Bacteriologic response by patients
The overall bacteriological eradication rate for patients
with either serological or culture-proven infection (combin-
ing end of therapy and follow-up responses) was 91% (106
of 116) (95% CI84%, 96%). Of the 10 patients
categorized as bacteriological failures at the follow-up visit,
three had persistent positive cultures (two C. pneumoniae,
oneM. pneumoniae), six were determined to have presumed
persistence due to clinical failure, and one had recurrence
with two organisms cultured (H. influenzae and E. coli).
Excluding patients who only met serological criteria, the
overall bacteriological response was 94% (60/64).
Overall bacteriological response rates for the intent-to-
treat population were also consistent with those of the valid
for ecacy population (92%; 113 of 123) (95% CI85%,
96%).
Bacteriologic response by organism
The overall bacteriological responses for each of the
causative organisms at the end of therapy (including
patients who only met serological criteria for microbiolo-
gically documented infection) are outlined in Table 5 for
the valid for ecacy population. The bacteriological
response was 93% each for M. pneumoniae and S.
pneumoniae, 89% each for C. pneumoniae and S. aureus,
and 85% for H. influenzae. The eradication rates for C.
pneumoniae and M. pneumoniae infections with pretherapy
positive cultures only were 67% (4/6) and 95% (21/22),
respectively.
SAFETY AND TOLERABILITY
Among 254 patients in the intent-to-treat population, 89%
received moxifloxacin for a total of 9–11 days. Eighteen
patients (7%) had the study drug discontinued prematurely
because of an adverse event (see Table 6). Two patients
each were discontinued for nausea, diarrhea, asthma and
rash. No other adverse events resulted in discontinuation of
more than one patient.
One hundred and twenty-two patients (48%) experienced
a treatment-emergent adverse event. Nausea (10%), diar-
rhea (8%) and dizziness (6%) were the most commonly
reported treatment-emergent events. C. diceal studies
were not routinely performed for patients who experienced
diarrhea. The majority of adverse events were considered
mild (44%) or moderate (34%) in intensity. Most adverse
events resolved during the course of the study (88%).Any drug-related adverse event was reported by the
investigator in 85 (33%) patients. Gastrointestinal-related
events were the most frequently reported drug-related
events (nausea, 9% and diarrhea, 6%) followed by drug-
related central nervous system event (dizziness, 4% and
insomnia, 2%). Rates of drug-related rash were low (2%).
Photosensitivity was not reported in any treated patients.
Discussion
This prospective, open-label multi-center study confirmed
that moxifloxacin 400 mg once daily for 10 days is a safe
and eective once daily oral treatment for patients with
CAP. The overall clinical and bacteriological response rates
were 93% and 91%, respectively. Clinical success was
excellent in patients with both typical and atypical
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for patients with typical pathogens (100%) compared to
those with atypical pathogens (93%), although this
dierence was not statistically significant. The bacteriolo-
gical response for individual respiratory tract pathogens
was comparable to the overall bacteriological response for
culture isolates and serologically confirmed pathogens
indicating that moxifloxacin is eective in eradicating
typical and atypical pathogens that commonly cause CAP.
As reported by others (6,7), slightly more than half
(58%) of the patients enrolled in the current trial had a
bacterial pathogen identified by culture or serology.
However, in contrast to earlier reports, S. pneumoniae
was isolated in only 8.4% of patients in the study (6.7). The
low rate of pneumococcal infection may be explained by the
relatively young age of patients enrolled in the current trial
(49 years) and the fact that patients with other serious
debilitating diseases or risk factors were excluded from the
study (e.g. nursing home residents). Another possible
reason is that the standard diagnostic techniques for
identifying the pneumococcus from expectorated sputum
lack sensitivity and specificity due to prior antibiotic
exposure, poor-quality specimens and delays in processing
(7). However, few patients in this trial received prior
antibiotics and sputum specimens were evaluated with a
Gram stain to determine the quality of the specimen.
C. pneumoniae and M. pneumoniae were the most
commonly identified bacteria in this study, 45% and
18%, respectively. The incidence ofMycoplasma pneumonia
as confirmed by serology was similar to that reported in the
literature (10–20%) (9,24,25). However, the 45% incidence
of Chlamydia pneumoniae as confirmed by serology and/or
culture tended to be higher than most previous studies of
CAP (24,25). In several studies conducted over the last
decade in ambulatory patients with CAP, the frequency of
serodiagnosis of C. pneumoniae was reported to range from
10–20% (9,24,25). The extensive eorts to identify C.
pneumoniae in this trial may explain the higher rates of
isolation. We should add that one site, which recruited 20
patients, saw no cases of C. pneumoniae or M. pneumoniae,
which is suggestive of geographical variation. Moreover,
one site in Spokane, WA, U.S.A. and one site in Boise, ID,
U.S.A. did report a higher porportion of patients with C.
pneumoniae infection than did other sites.
The prevalence of Chlamydia pneumonia in clinical
studies may vary depending on the culture or serological
methods employed and the patient population studied
(9,26,27). In the present study, the mean age of patients
with Chlamydia pneumoniae identified was 49, the same as
the overall mean age. Serodiagnosis of C. pneumoniae was
based on an established algorithm which required that one
of the following three criteria be satisfied: 1. Four-fold
increase in IgG between any two visits, 2. IgM1:32 at any
visit and 3. IgG1:512 at any visit. It is recognized that the
most rigorous and specific criterion is demonstration of a 4-
fold increase in IgG titer, and that the least rigorous and
specific criterion is single high-titer elevation of IgG
(IgG1:512). While the algorithm described above is
frequently used, in some reports, high-titer IgG elevations
are not included in the diagnostic criteria for acuteC. pneumoniae infection (27). It is possible that many of
the single high-titer elevations of IgG in our patients were
indicative of previous of chronic infection with
C. pneumoniae. However 17 of 60 patients who met the
serological criteria for C. pneumoniae elevation had
IgM titers1:32 at any visit, a finding consistent with
acute infection. In addition, 10 of 60 patients that met
the overall serological criteria for C. pneumoniae also had a
4-fold increase in IgG titer while three patients who met the
overall serological criteria also had positive Chlamydia
cultures. To confirm the IgM findings, serological testing
for IgM C. pneumoniae antibodies was repeated using the
sera from 20 patients with detectable IgM titer, with and
without rheumatoid factor absorption (28). IgM titers on
repeat micro-immunofluorescence testing after rheumatoid
factor absorption were similar to those originally reported.
Most patients had a significant change in IgM titer
rheumatoid factor absorption; IgM titers after rheumatoid
factor absorption were less than 1:32 in sera from two of 15
patients reported as1:32 (original and repeat testing
without rheumatoid factor absorption).
Although special culture techniques are available for
M. pneumoniae and C. pneumoniae, few laboratories
routinely cultivate for the these pathogens in the clinical
setting. Accordingly, the true prevalence of these latter
atypical pathogens is not well known because of limitations
in diagnostic sensitivity, specificity and availability. The
current trial stresses the importance of using empiric
therapy with reliable atypical coverage when treating
patients with CAP and the need for continued surveillance
for atypical pathogens as important causes of CAP.
The exponential growth of bacterial resistance in the
U.S.A. will ultimately lead to increased healthcare costs,
namely due to the increased chance that initial empiric
antimicrobial therapy will be inappropriate, ultimately
resulting in increased hospital admissions or an increased
length of hospital stay. Although pharmacoeconomic data
were not collected in the current trial, treatment with
moxifloxacin provided high clinical and bacteriological
success rates. The clinical and economic benefits of
moxifloxacin compared to other standard b-lactam or
macrolide antimicrobials remains to be evaluated in large
controlled trials in patients with CAP stratified by
comorbidities.
In this first non-comparative CAP clinical trial with
moxifloxacin, the quinolone was found to be safe and well
tolerated. As reported for other available fluorquinolones,
nausea, diarrhea and dizziness were the most commonly
reported drug-related events, occurring in 9%, 6% and 4%
of patients, respectively. It is worth emphasizing, however
that only two patients were discontinued for nausea and
diarrhea, and only one patient for dizziness. In addition,
photosensitivity was not reported for any patient during the
trial’s surveillance period. Most of the adverse events
reported were mild to moderate in intensity and resolved
without medical intervention.
The selection of an empiric therapy for the treatment of
patients with CAP is not always a straightforward decision
for the clinician. In the majority of cases, initial empiric
therapy is, by necessity, broad in spectrum. If the patient
104 T. PATEL ET AL.can be managed in the outpatient setting, oral therapy that
is convenient (e.g. once a day), safe, lacking in clinically
significant drug interactions and capable of eradicating
both typical and atypical pathogens is desirable. Appro-
priate modifications of therapy can subsequently be made
based upon the patient’s clinical progress and available
microbiological data. Newer fluoroquinolones with ex-
panded Gram-positive activity have recently been recom-
mended by the Infectious Disease Society of America as
empiric agents for treatment of CAP, especially as
resistance to b-lactams and macrolides becomes more
prevalent (7). In summary, moxifloxacin was found in this
trial to be an eective and safe treatment for CAP with
excellent in vivo activity against typical, including Gram-
positive organisms, and atypical respiratory pathogens.
Moxifloxacin is an attractive treatment alternative for
patients with CAP who qualify for oral anti-infective
therapy and oers the convenience of once a day dosing.
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